Source: Baltimore Sun
Posted: October 20, 2006
Summary:
Baltimore's Osiris Therapeutics announced results of a 10-person clinical trial of an experimental stem-cell treatment. Preliminary data show that all 10 patients in the mid-stage clinical trial saw a reduction in symptoms after receiving intravenous infusions of the adult stem-cell treatment, and three of them went into temporary remission.
The drug, which analysts say is close to becoming the first pure stem cell product on the market, is already under investigation as a treatment for a rare condition associated with bone marrow transplants. But if it also gains approval as a therapy for Crohn's disease - and possibly its cousin Irritable Bowel Syndrome - the drug Prochymal could be the first stem-cell product with a large application as well as a big breadwinner for the newly public Osiris.
Commentary: Hopefully the trial of this drug will yield successful results and prove to be an effective treatment for bowel disease
No comments:
Post a Comment